Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib—Report of Three Cases

Pazopanib is a potent multi-kinase inhibitor that hinders angiogenesis and blocks tumor growth. It has been approved for the treatment of metastatic renal cell carcinoma (mRCC) and advanced soft tissue sarcoma. There is emerging evidence that bleeding is a common adverse effect of pazopanib and othe...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadopoulou, Erofili, Vardas, Emmanouil, Tziveleka, Styliani, Georgaki, Maria, Kouri, Maria, Katoumas, Konstantinos, Piperi, Evangelia, Nikitakis, Nikolaos G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777138/
https://www.ncbi.nlm.nih.gov/pubmed/36547048
http://dx.doi.org/10.3390/dj10120232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777138/
https://www.ncbi.nlm.nih.gov/pubmed/36547048
http://dx.doi.org/10.3390/dj10120232

Ejemplares similares